These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 17311012)
1. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. Lickliter JD; Cox J; McCarron J; Martinez NR; Schmidt CW; Lin H; Nieda M; Nicol AJ Br J Cancer; 2007 Feb; 96(4):600-8. PubMed ID: 17311012 [TBL] [Abstract][Full Text] [Related]
2. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354 [TBL] [Abstract][Full Text] [Related]
3. [Progress in small-molecule inhibitors of Bcl-2 family proteins]. Tang Y; Zhang DY; Wu XM Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468 [TBL] [Abstract][Full Text] [Related]
4. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965 [TBL] [Abstract][Full Text] [Related]
6. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110 [TBL] [Abstract][Full Text] [Related]
7. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104 [TBL] [Abstract][Full Text] [Related]
9. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430 [TBL] [Abstract][Full Text] [Related]
10. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354 [TBL] [Abstract][Full Text] [Related]
11. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Hao JH; Yu M; Liu FT; Newland AC; Jia L Cancer Res; 2004 May; 64(10):3607-16. PubMed ID: 15150119 [TBL] [Abstract][Full Text] [Related]
12. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435 [TBL] [Abstract][Full Text] [Related]
13. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity. Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701 [TBL] [Abstract][Full Text] [Related]
15. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658 [TBL] [Abstract][Full Text] [Related]